Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BCMA bispecific Clear all

Conditions: Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Interventions: Velinotamig specified dose on specified days.; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Webster, Texas

Conditions: Multiple Myeloma
Interventions: Talquetamab, Teclistamab; Drug
Lead sponsor: Noffar Bar; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: New Haven, Connecticut • Omaha, Nebraska • Rochester, New York

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Denver, Colorado + 9 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Daratumumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 26
States / cities: Clovis, California • Fresno, California • Fort Collins, Colorado + 17 more

Conditions: AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Interventions: OM336; Drug
Lead sponsor: Lakefront Biotherapeutics West LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 1 more

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Fludeoxyglucose F-18, Immunotherapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 74 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Myeloma
Interventions: Elranatamab, Carfilzomib, Maplirpacept; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 31
States / cities: Little Rock, Arkansas • Beverly Hills, California • Encino, California + 15 more

Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions: REGN5459; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Rochester, Minnesota + 4 more

Conditions: Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fort Collins, Colorado + 20 more

Conditions: Amyloid Light-chain Amyloidosis
Interventions: BCMA bispecific; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Hematological Malignancies
Interventions: Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Standard of Care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 14
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Multiple Myeloma
Interventions: Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Lenalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 24
States / cities: Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 14 more

Conditions: Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 17
States / cities: Irvine, California • Orange, California • Fort Collins, Colorado + 9 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Standard of care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Etentamig, Positron Emission Tomography, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Elranatamab, Standard of care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: TNB-383B; Drug
Lead sponsor: TeneoOne Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Multiple Myeloma
Interventions: Elranatamab (PF-06863135); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 37
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 17 more

Conditions: Multiple Myeloma
Interventions: Elranatamab (PF-06863135); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 33
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 16 more

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more

Conditions: Multiple Myeloma
Interventions: Cevostamab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Aurora, Colorado • Jacksonville, Florida • Baltimore, Maryland + 5 more

Search by objective public record fields.

A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

OM336 in Autoimmune Cytopenias

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma